Advertisement


Michael Unterhalt, MD, on Mantle Cell Lymphoma: Long-Term Follow-up Results

2017 ASH Annual Meeting

Advertisement

Michael Unterhalt, MD, of the University Hospital Grosshadern, discusses study findings on rituximab maintenance after first-line immunochemotherapy among older patients who are not candidates for autologous stem cell transplantation (Abstract 153).



Related Videos

Lymphoma

Jakub Svoboda, MD, on Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, and Gray Zone Lymphomas: Early-Phase Treatment Findings

Jakub Svoboda, MD, of the Abramson Cancer Center, University of Pennsylvania, discusses some encouraging phase I/II results on brentuximab vedotin with R-CHP chemotherapy as front-line treatment of CD30-positive primary mediastinal large B-cell, diffuse large B-cell, and gray zone lymphomas (Abstract 191).

Leukemia

Nitin Jain, MD, on CLL: Results From a Venetoclax/Ibrutinib Trial

Nitin Jain, MD, of The University of Texas MD Anderson Cancer Center, discusses phase II study results on combined venetoclax and ibrutinib for patients with previously untreated high-risk and relapsed/refractory chronic lymphocytic leukemia (Abstract 429).

Leukemia

John F. Seymour, MBBS, PhD, on CLL: Results From the MURANO Study

John F. Seymour, MBBS, PhD, of the Peter MacCallum Cancer Centre, discusses an interim analysis of venetoclax plus rituximab vs bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia (Abstract LBA-2).

Lymphoma

Jia Ruan, MD, on Mantle Cell Lymphoma: Study Results on Lenalidomide and Rituximab

Jia Ruan, MD, of NewYork-Presbyterian/Weill Cornell Medical Center, discusses a 5-year follow-up analysis that showed lenalidomide and rituximab as initial treatment achieved a high rate of complete responses and MRD negativity with durable remissions beyond 4 years (Abstract 154).

Hematologic Malignancies
Issues in Oncology
Cost of Care

Alok A. Khorana, MD, on The Costs of VTE in Cancer Patients: Expert Perspective

Alok A. Khorana, MD, of the Cleveland Clinic, discusses the prevalence of venous thromboembolism in cancer patients treated at U. S. emergency departments and associated costs, mortality, and hospital admissions in the United States (Abstract 219).

Advertisement

Advertisement



Advertisement